Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 3 from your keywords: subject="leukemia"
cover
IFM is a Potential Key Player in AML Cell Survival and CML Cell Resistance to…
Comment Share
Michelle Danisa

Myeloid leukemia is characterized by the excessive proliferation of myeloid cells within the bone marrow. It is categorized into acute (AML) and chronic (CML) myeloid leukemia, with distinct etiologies and therapeutic complexities. The genetic heterogeneity of AML contributes to varying treatment responses, leading to a high mortality rate. One gene that has been identified as an adverse pro…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
BM 24-037
cover
Validating hit genes from CRISPR screening on response toward combinations of…
Comment Share
Deanna Hannah Maringka

Acute myeloid leukemia (AML) is a heterogenous blood cancer disease that develops from the stem cell precursors which the myeloid lineage happened due to genetic lesion that leads to overproduction and failure to differentiate these myeloid blast cells. A mutation in the FMS-like tyrosine kinase 3 (FLT3) gene, is the most frequent genetic lesion in AML patients, this mutation is linked with a p…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
BM 23-031
cover
The Impact of CEBPA gene Mutation on Cell Morphology and Immunophenotyping in…
Comment Share
NAFTALIE CHRISTABEL TANTOKUSUMO

Acute myeloid leukemia (AML) is a type of blood cancer that develops due to DNA mutations in the stem cells. AML survival rates show only 30.5% which significantly contributes to the number of cancer-related mortality. One of the altered genes that are frequently identified in AML patients is CEBPA. The CEBPA gene encodes the C/EBPɑ-p42 and C/EBPɑ-p30 that consist of C-terminal and N-termi…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
BM 22-015